Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Depreciation & Amortization (CF) (2022 - 2025)

Zentalis Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 4 years, most recently at $118000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $118000.0 for Q4 2025, down 64.02% from a year ago — trailing twelve months through Dec 2025 was $700000.0 (down 46.15% YoY), and the annual figure for FY2025 was $700000.0, down 46.15%.
  • Depreciation & Amortization (CF) for Q4 2025 was $118000.0 at Zentalis Pharmaceuticals, down from $160000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for ZNTL hit a ceiling of $375000.0 in Q3 2022 and a floor of $118000.0 in Q4 2025.
  • Median Depreciation & Amortization (CF) over the past 4 years was $325500.0 (2024), compared with a mean of $294250.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): increased 13.49% in 2024 and later crashed 64.02% in 2025.
  • Zentalis Pharmaceuticals' Depreciation & Amortization (CF) stood at $300000.0 in 2022, then fell by 3.67% to $289000.0 in 2023, then rose by 13.49% to $328000.0 in 2024, then crashed by 64.02% to $118000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $118000.0 (Q4 2025), $160000.0 (Q3 2025), and $160000.0 (Q2 2025) per Business Quant data.